Albiglutide

Albiglutide (formerly GSK716155, marketed as Tanzeum in the US and Eperzan in Europe) was a once-weekly GLP-1 receptor agonist developed by GlaxoSmithKline for the treatment of type 2 diabetes mellitus. The compound was a recombinant fusion protein consisting of two tandem copies of modified human GLP-1(7-36 amide) genetically fused to the N-terminus of recombinant human serum albumin. The albumin fusion conferred an extended half-life of approximately 5 days, allowing once-weekly subcutaneous administration. The compound received EMA approval as Eperzan in March 2014 and FDA approval as Tanzeum in April 2014. Approval was supported by the HARMONY Phase 3 program comprising 8 clinical trials with more than 5000 patients. Despite the convenience of once-weekly dosing and competitive pricing, albiglutide had lower HbA1c reduction and less weight loss than competing GLP-1 agonists. GSK announced worldwide market withdrawal in July 2017 citing commercial reasons. Remaining stocks were depleted by July 2018. The HARMONY Outcomes cardiovascular trial published in The Lancet in October 2018 demonstrated 22% reduction in major adverse cardiovascular events, but the result came too late to reverse the commercial decision.

Development and Structure

Albiglutide was developed by Human Genome Sciences (HGS) using their albumin fusion technology. The compound was acquired by GlaxoSmithKline through the 2012 GSK acquisition of HGS. The molecular structure is distinctive among GLP-1 agonists: rather than a small modified peptide (like liraglutide or semaglutide), albiglutide is a 73 kDa recombinant fusion protein consisting of two tandem copies of modified GLP-1(7-36 amide), each with an Ala8Gly substitution to resist DPP-4 degradation, genetically fused to the N-terminus of recombinant human serum albumin. The albumin component provides the extended half-life through albumin's natural recycling via the neonatal Fc receptor.

The fusion protein structure has practical consequences: large molecular size (73 kDa) is much larger than small-peptide GLP-1 agonists, lower potency per molecule than small-peptide agonists at the GLP-1 receptor due to steric effects, reduced gastrointestinal side effects possibly due to slower target tissue penetration, higher rate of injection site reactions possibly due to immunogenicity, and higher manufacturing costs due to mammalian cell expression requirements.

The HARMONY Phase 3 Program

The HARMONY Phase 3 development program was the principal evidence base supporting FDA approval. The program comprised 8 randomized clinical trials enrolling more than 5000 patients, including more than 2000 patients on albiglutide.

HARMONY 1: albiglutide vs placebo as add-on to pioglitazone with or without metformin.

HARMONY 2: albiglutide vs placebo as monotherapy. HbA1c reduction of approximately 0.7-0.8%.

HARMONY 3: albiglutide vs placebo and sitagliptin and glimepiride as add-on to metformin.

HARMONY 4: albiglutide vs insulin glargine as add-on to metformin. Comparable HbA1c reduction with less hypoglycemia.

HARMONY 5: albiglutide vs placebo as add-on to metformin and glimepiride.

HARMONY 6: albiglutide as add-on to insulin glargine vs prandial insulin lispro.

HARMONY 7: albiglutide vs liraglutide head-to-head. Albiglutide produced less HbA1c reduction (-0.78% vs -0.99%, difference 0.21%, p<0.05) and less weight loss (-0.64 kg vs -2.19 kg) than liraglutide. This was the key relative efficacy disadvantage.

HARMONY 8: albiglutide in patients with renal impairment.

The HARMONY 7 result was clinically meaningful: albiglutide was inferior to liraglutide in head-to-head comparison for both glycemic control and weight loss. The relative efficacy disadvantage became a major commercial liability.

HARMONY Outcomes Cardiovascular Trial

HARMONY Outcomes (Hernandez 2018 Lancet) was the cardiovascular outcomes trial conducted to satisfy FDA cardiovascular safety requirements. The trial enrolled 9463 patients with type 2 diabetes and established cardiovascular disease, randomized 1:1 to albiglutide 30-50 mg once weekly vs placebo. Median follow-up was 1.6 years. The primary endpoint was time to first occurrence of major adverse cardiovascular events (MACE): cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke.

Results: albiglutide reduced the primary cardiovascular endpoint by 22%. Hazard ratio 0.78 (95% CI 0.68-0.90, p=0.0006 for superiority). The result demonstrated cardiovascular benefit comparable in magnitude to LEADER (liraglutide, 13% reduction), SUSTAIN-6 (semaglutide, 26% reduction), and REWIND (dulaglutide, 12% reduction).

The critical timing issue: GSK announced worldwide market withdrawal in July 2017. HARMONY Outcomes was published in October 2018, more than a year later. The cardiovascular benefit result came too late to reverse the commercial decision.

GSK Discontinuation Decision

In July 2017, GSK announced worldwide market withdrawal of albiglutide. The official reason was "commercial factors" rather than safety or efficacy concerns. Contributing factors: lower glycemic efficacy than competing GLP-1 agonists (HARMONY 7 vs liraglutide), less weight loss than other GLP-1 agonists, increased injection site reactions vs competitors, once-weekly dulaglutide (Trulicity, Eli Lilly) launched in September 2014 with similar dosing convenience and superior efficacy, slow Tanzeum sales growth in a competitive market, GSK strategic refocus away from diabetes therapeutic area, and high cost of mammalian cell manufacturing for the fusion protein.

The withdrawal was implemented in phases: July 2017 discontinuation announcement, late 2017-mid 2018 phasing out manufacturing, July 2018 remaining stocks depleted in US, patients transitioned to alternative GLP-1 agonists, and FDA approval status administratively withdrawn.

Lessons from the Albiglutide Story

The albiglutide commercial failure provides several lessons for the GLP-1 development landscape: head-to-head efficacy trials are commercially decisive in crowded markets, manufacturing complexity increases costs, first-to-market advantages matter, cardiovascular benefit requires timely demonstration, and the GLP-1 class is unforgiving of weak efficacy entries.

Regulatory Status

• FDA: Tanzeum (NDA 125431) approved April 15, 2014. Worldwide withdrawal announced July 2017. Remaining US stocks depleted July 2018
• EMA: Eperzan approved March 21, 2014. Marketing authorization withdrawn at GSK request
• Other regions: withdrawn following the global discontinuation
• WADA: Not on the prohibited list

Albiglutide was a full agonist at the glucagon-like peptide-1 receptor (GLP-1R), with the same fundamental mechanism as other GLP-1 receptor agonists but with distinctive features arising from the albumin fusion structure.

GLP-1 Receptor Biology

GLP-1 is an incretin hormone secreted by intestinal L-cells in response to food intake. It is rapidly degraded by dipeptidyl peptidase-4 (DPP-4) in plasma. The biological effects of GLP-1 receptor activation include glucose-dependent insulin secretion from pancreatic beta cells, glucagon suppression from pancreatic alpha cells, delayed gastric emptying, central appetite suppression in hypothalamic regions, and beneficial effects on cardiovascular tissues, kidneys, and other organ systems.

Albumin Fusion Structure

Albiglutide differs from other GLP-1 agonists through its albumin fusion structure. The molecule consists of two tandem copies of modified GLP-1(7-36 amide) with Ala8Gly substitutions to resist DPP-4 degradation, fused to the N-terminus of recombinant human serum albumin. Total molecular weight is approximately 73 kDa, much larger than small-peptide GLP-1 agonists (semaglutide is approximately 4.1 kDa, liraglutide approximately 3.8 kDa).

The albumin fusion produces an extended half-life of approximately 5 days through natural albumin recycling mediated by the neonatal Fc receptor (FcRn). Albumin has a normal serum half-life of about 19 days through FcRn-mediated recycling. The albumin-fused GLP-1 inherits much of this protection. The result is a long-acting GLP-1 receptor agonist suitable for once-weekly dosing.

Functional Consequences of the Fusion Structure

The fusion structure has practical pharmacological consequences. Lower potency per molecule at GLP-1R due to steric hindrance from the large albumin component, reduced central nervous system penetration possibly explaining lower central appetite-suppressing effects and less weight loss, reduced gastrointestinal effects possibly related to reduced tissue penetration resulting in less nausea than smaller GLP-1 agonists, and increased immunogenicity with higher rates of injection site reactions possibly due to immune responses to the fusion construct.

Pharmacokinetics

• Half-life: approximately 5 days
• Time to maximum concentration: 3-5 days after subcutaneous injection
• Steady state: achieved after 4-5 weekly doses
• Volume of distribution: approximately 11 liters
• Bioavailability: approximately 80% subcutaneous
• Metabolism: degraded by general proteolysis (similar to albumin)
• Elimination: through general protein catabolism

Clinical Pharmacology

Despite the lower in vitro potency, albiglutide produced clinically meaningful GLP-1 receptor activation at therapeutic doses through sustained exposure. The pharmacological consequences included sustained reduction in fasting glucose, moderate reduction in postprandial glucose, modest weight loss (less than other GLP-1 agonists due to reduced CNS penetration), reduced glucagon levels, and modest blood pressure reduction.

The cardiovascular benefit demonstrated in HARMONY Outcomes was unexpected given the lower in vitro potency, but mechanistically consistent with GLP-1 receptor class effects on cardiovascular tissues.

Effects in registrational HARMONY clinical trials:

• HbA1c reduction of 0.6-0.9% at 24-52 weeks
• Modest fasting glucose reduction
• Modest postprandial glucose reduction
• Weight loss typically 0.5-2 kg (less than other GLP-1 agonists)
• Reduced glucagon levels
• Modest blood pressure reduction
• Modest improvement in lipid parameters
• Less HbA1c reduction than liraglutide (HARMONY 7)
• Less weight loss than liraglutide (HARMONY 7)
• Comparable HbA1c reduction to insulin glargine with less hypoglycemia (HARMONY 4)

Effects in cardiovascular outcomes trial (HARMONY Outcomes, Hernandez 2018 Lancet):

• 22% reduction in major adverse cardiovascular events (MACE) (HR 0.78, p=0.0006)
• Reduction in non-fatal myocardial infarction (HR 0.75)
• Reduction in non-fatal stroke (HR 0.86)
• No significant effect on heart failure hospitalization
• Cardiovascular benefit comparable in magnitude to LEADER (liraglutide) and REWIND (dulaglutide)

Comparison to other GLP-1 agonists:

• HbA1c reduction: less than semaglutide, dulaglutide, liraglutide
• Weight loss: less than all other GLP-1 agonists
• GI side effects: less than liraglutide and exenatide
• Injection site reactions: more common than other GLP-1 agonists
• Cardiovascular benefit: comparable to other GLP-1 agonists with proven CV benefit
• Manufacturing complexity: significantly higher than peptide GLP-1 agonists

Honest evidence framing: Albiglutide had robust clinical evidence from the HARMONY Phase 3 program and the HARMONY Outcomes cardiovascular trial. The compound demonstrated cardiovascular benefit (22% MACE reduction) that would have positioned it as a useful GLP-1 option. The commercial failure was driven by inferior glycemic efficacy and weight loss vs liraglutide, increased injection site reactions, and intense competition. The withdrawal was a commercial decision rather than safety or efficacy failure. The albiglutide story illustrates that in a crowded therapeutic class, head-to-head efficacy inferiority can be commercially fatal even when absolute efficacy is clinically meaningful and cardiovascular benefit is demonstrated.

Historical note: albiglutide is no longer available. Dosing information below reflects the FDA-approved Tanzeum regimen from 2014-2018 for historical reference.

FDA-approved Tanzeum dosing:

• Starting dose: 30 mg subcutaneously once weekly
• Maintenance dose: 30 mg or 50 mg once weekly based on glycemic response
• Maximum dose: 50 mg once weekly
• Administration: any day of the week, regardless of meals
• Dose interval: at least 4 days between doses if changing dosing day
• Product: single-dose injector pen with reconstitution required immediately before injection
• Injection sites: abdomen, thigh, or upper arm; rotate sites
• Storage: refrigerate at 2-8°C; once activated, use within 8 hours

Dose adjustments:

• Renal impairment: no adjustment needed for mild-moderate renal impairment. Caution in severe renal impairment. Not recommended in end-stage renal disease
• Hepatic impairment: no specific adjustment recommended; limited data
• Elderly patients: no specific adjustment, monitor renal function
• Pediatric patients: not studied, not approved

Combination therapy (historical):

• Albiglutide + metformin: standard combination
• Albiglutide + sulfonylurea: consider reducing sulfonylurea dose
• Albiglutide + pioglitazone: standard combination
• Albiglutide + insulin: powerful combination
• Albiglutide + DPP-4 inhibitors: not recommended (mechanism overlap)
• Albiglutide + other GLP-1 agonists: not recommended

Drug interactions: albiglutide delayed gastric emptying, which could affect absorption of oral medications. Insulin and sulfonylureas carried additive hypoglycemia risk.

Special populations (historical): pregnancy not recommended, breastfeeding not recommended, pediatric not studied, type 1 diabetes not appropriate, history of pancreatitis contraindicated, medullary thyroid carcinoma or MEN-2 boxed warning and contraindicated.

Adverse effects from FDA-approved Tanzeum clinical trials and post-marketing experience (historical):

Common adverse effects (5% or more):

• Upper respiratory tract infections (15%)
• Diarrhea (13%)
• Injection site reactions (12%, notably higher than other GLP-1 agonists)
• Nausea (11%)
• Back pain (8%)
• Sinusitis (7%)
• Cough (7%)
• Hypoglycemia (when combined with sulfonylureas or insulin)

Compared to other GLP-1 agonists, albiglutide had lower rates of nausea and vomiting, but higher rates of injection site reactions. The injection site reactions were a distinctive feature, possibly related to immunogenicity of the recombinant fusion protein.

Less common but clinically important:

• Acute pancreatitis: rare but serious (class effect for all GLP-1 agonists)
• Anaphylaxis and serious hypersensitivity reactions: post-marketing FDA warning issued
• Severe injection site reactions: severe reactions could occur
• Acute kidney injury: particularly in dehydrated patients
• Hypoglycemia (when combined with sulfonylureas or insulin)
• Thyroid C-cell carcinoma: boxed warning based on rodent studies

Boxed Warning: Risk of thyroid C-cell tumors. Albiglutide and other GLP-1 receptor agonists caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in rodents. Contraindicated in patients with personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).

Contraindications:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN-2)
• History of severe hypersensitivity to albiglutide
• History of acute pancreatitis (consider alternative therapy)

Pregnancy: limited human data. Animal studies showed some fetal effects.

Breastfeeding: limited data, not recommended.

Pediatric: not studied, not approved.

Cardiovascular safety: established by HARMONY Outcomes trial with 22% MACE reduction.

Albiglutide is no longer available. This section discusses its historical position in the GLP-1 receptor agonist class:

Direct comparator GLP-1 agonists (currently available in 2026):

• Dulaglutide: once-weekly long-acting GLP-1 agonist (Trulicity, Eli Lilly). FDA-approved 2014. The principal commercial winner against albiglutide in the once-weekly category. Greater HbA1c reduction and weight loss than albiglutide. Cardiovascular benefit demonstrated in REWIND
• Exenatide: synthetic exendin-4. Twice-daily Byetta (discontinued 2024) or weekly Bydureon. The first GLP-1 agonist on the market
• Liraglutide: once-daily long-acting GLP-1 agonist (Victoza for diabetes, Saxenda for obesity). Greater HbA1c reduction and weight loss than albiglutide. Cardiovascular benefit demonstrated in LEADER trial
• Semaglutide: weekly long-acting GLP-1 agonist (Ozempic for diabetes, Wegovy for obesity, Rybelsus oral). The current leader in efficacy. Cardiovascular benefit in SUSTAIN-6

Patient transition pathways (historical, 2017-2018):

When GSK announced the worldwide withdrawal in July 2017, patients on albiglutide were transitioned to alternative GLP-1 agonists. Common transitions included albiglutide to dulaglutide (Trulicity), albiglutide to liraglutide (Victoza), and albiglutide to once-weekly exenatide (Bydureon).

Implications for GLP-1 product development:

The albiglutide commercial failure has shaped subsequent GLP-1 development decisions: head-to-head efficacy trials are now essential for successful GLP-1 launches, cardiovascular outcomes trials need to be completed before launch in competitive markets, fusion protein structures face manufacturing cost disadvantages vs peptide approaches, weight loss is now equally important to glycemic efficacy as a commercial endpoint, and the bar for commercial viability in the GLP-1 class continues to rise.

The most actionable framing of albiglutide in 2026: this is a historical reference compound rather than a current treatment option. Albiglutide was a once-weekly GLP-1 receptor agonist (Tanzeum, Eperzan) FDA-approved in 2014 and withdrawn worldwide by GSK in 2017-2018 for commercial reasons. The product had robust clinical evidence including a Phase 3 program with 5000+ patients and cardiovascular benefit demonstrated in HARMONY Outcomes (published October 2018, after the withdrawal decision). The commercial failure was driven by inferior glycemic efficacy and weight loss vs liraglutide in the HARMONY 7 head-to-head trial, increased injection site reactions, intense competition from established GLP-1 agonists, and GSK's strategic refocus. The albiglutide story illustrates how head-to-head efficacy inferiority can be commercially fatal in a crowded therapeutic class. For current type 2 diabetes management in 2026, semaglutide, dulaglutide, and tirzepatide dominate the GLP-1 receptor agonist market, with substantially greater efficacy than albiglutide ever achieved.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.